SCM
TRDA icon

Sterling Capital Management’s Entrada Therapeutics TRDA Stock Holding History

Sterling Capital Management’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.9K Sell
943
-697
-43% -$7.99K ﹤0.01% 2283
2025
Q4 		$16.9K Sell
1,640
-301
-16% -$2.54K ﹤0.01% 2322
2025
Q3 		$11.3K Buy
1,941
+1,244
+178% +$7.28K ﹤0.01% 2426
2025
Q2 		$4.68K Buy
697
+271
+64% +$2.18K ﹤0.01% 2546
2025
Q1 		$3.85K Sell
426
-366
-46% -$4.56K ﹤0.01% 2289
2024
Q4 		$13.7K Buy
792
+702
+780% +$12.7K ﹤0.01% 2012
2024
Q3 		$1.44K Buy
+90
New +$1.42K ﹤0.01% 2356

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sterling Capital Management's TRDA Position: Q1 2026 in Review

Sterling Capital Management reduced its Entrada Therapeutics (TRDA) stake by 43% in Q1 2026, selling an estimated $7.99K and leaving 943 shares worth $11.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2283.

Sterling Capital Management first reported a position in TRDA in Q3 2024 and has held it in 7 quarters since. The position peaked at $16.9K in Q4 2025. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

  • Sterling Capital Management held 943 shares of Entrada Therapeutics worth $11.9K as of Q1 2026.
  • Sterling Capital Management sold 697 Entrada Therapeutics shares in Q1 2026, an estimated $7.99K.
  • Entrada Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #2283 holding.
  • Sterling Capital Management first reported a position in Entrada Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Sterling Capital Management's Entrada Therapeutics position peaked at $16.9K in Q4 2025.
  • 120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.